ROSGQ (Rosetta Genomics) YoY EBITDA Growth: 46.63% (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rosetta Genomics YoY EBITDA Growth?

Rosetta Genomics ROSGQ YoY EBITDA Growth is 46.63% as of Jun. 2017.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Rosetta Genomics's YoY EBITDA Growth for the quarter that ended in Jun. 2017 was 46.63%.

Rosetta Genomics's EBITDA per Share for the six months ended in Jun. 2017 was $-1.98.

Rosetta Genomics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics YoY EBITDA Growth Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.92 25.31 6.00 13.13 33.11

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 19.39 52.06 17.20 46.63

Rosetta Genomics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Rosetta Genomics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2016 is calculated as:

YoY EBITDA Growth (A: Dec. 2016 )
=(EBITDA per Share (A: Dec. 2016 )-EBITDA per Share (A: Dec. 2015 ))/ | EBITDA per Share (A: Dec. 2015 ) |
=(-8.789--13.14)/ | -13.14 |
=33.11 %

Rosetta Genomics's YoY EBITDA Growth for the quarter that ended in Jun. 2017 is calculated as:

YoY EBITDA Growth (Q: Jun. 2017 )
=(EBITDA per Share (Q: Jun. 2017 )-EBITDA per Share (Q: Jun. 2016 )) / | EBITDA per Share (Q: Jun. 2016 )) |
=(-1.982--3.714)/ | -3.714 |
=46.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 46.63% mean?
Rosetta Genomics (ROSGQ) has a YoY EBITDA Growth of 46.63% as of Jun. 2017. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Rosetta Genomics and its competitors.
Is Rosetta Genomics' YoY EBITDA Growth too high?
Rosetta Genomics' current YoY EBITDA Growth is 46.63%.
How does Rosetta Genomics' YoY EBITDA Growth compare to TEAR and IDTA?
Rosetta Genomics' YoY EBITDA Growth of 46.63% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Rosetta Genomics and its competitors. Rosetta Genomics's current YoY EBITDA Growth is 46.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current YoY EBITDA Growth of 46.63%. The current YoY EBITDA Growth is 46.63%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current YoY EBITDA Growth is 46.63% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.